Is Gilead Sciences entering a bold new era?

What even happened in 2018? And how useful is a genetic credit score?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we pick apart Gilead’s decision to appoint a pharma veteran to serve as its next CEO and guess at what’s in store for the bellwether company in 2019. Then Emory University epidemiologist Cecile Janssens joins us to talk about what you can and absolutely can’t learn from genetic tests. And finally we look back at the year that was in biotech, digging into all the criminal chicanery, counter-intuitive goings-on, and actual scientific progress.

You can listen to the episode here. To listen to future episodes, be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.